| Carcinoma altered in cohorts of …ALTERED_INderived200 of 1,338show all (up to 200) |
|---|
| ← altered in cohorts of | CD40 151 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNF4A 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCK1 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RIMS4 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SGK2 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRPC4AP 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BLCAP 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP7 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BPI 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BPIFB3 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COX4I2 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EDN3 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMILIN3 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM83D 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FOXS1 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GCNT7 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HM13 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH8 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYL9 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGT 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBM39 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPN2 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC35C2 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC9A8 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPO11 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SUN5 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADIG 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C20orf173 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNBD2 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPPIN-WFDC6 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ERGIC3 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM209B 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM210B 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAFB 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MMP24 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSBPL2 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSER1 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAE1 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RTF2 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERINC3 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAI1 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP53RK 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VAPB 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WFDC11 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WFDC13 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WFDC3 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf158 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMK2N1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMTA1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAPZB 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCN6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDOST 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | E2F2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM43B 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO42 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMGCL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPR 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HP1BP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR1D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IFFO2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF21 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KDM1A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LACTBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LDLRAD2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC38 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LUZP1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFAP2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10-NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MST1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPHP4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OTUD3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAX7 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDIK1L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDPN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PINK1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PITHD1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2C 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2E 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2F 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHG5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF12 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF14 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF18 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF20 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF25 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF26 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF27 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF33 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF9 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAP1GAP 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCC2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF186 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC66A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TEX46 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP48 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF436 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC3A 20 / 25 cases (80 %) · ssm · cscc_ranson_2022 | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PPP1R3A 20 / 25 cases (80 %) · ssm · cscc_ranson_2022 | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AVPR1A 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BAZ2A 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAND1 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSD17B6 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NACA 70 / 92 cases (76 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AGAP2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP23 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP5F1B 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AVIL 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BIN2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDK4 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTDSP2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYP27B1 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DYRK2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT3 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FRS2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL22 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MARCHF9 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | METTL1 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OS9 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRIM1 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTGES3 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBMS2 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STAT6 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSFM 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSPAN31 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB39 69 / 92 cases (75 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DIDO1 345 / 461 cases (75 %) · ssm · TCGA-COAD | — | — | Colon Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APC 5,400 / 7,237 cases (75 %) · ssm · crc_msk_2026 · largest of 19 cohorts | — | — | Rectal Adenocarcinoma | 19 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MYC 138 / 185 cases (75 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POU5F1B 138 / 185 cases (75 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNB1 343 / 461 cases (74 %) · ssm · TCGA-COAD · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ANKRD52 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP9 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF25 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | B4GALNT1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BEST3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C12orf66 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CELA1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPM 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CSRNP2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCTN2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDIT3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPY19L2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DTX3 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESYT1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLI1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLS2 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNS 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR182 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRIP1 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HDAC7 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HIGD1C 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL26 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INHBC 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INHBE 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF5A 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRT74 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRT75 68 / 92 cases (74 %) · ssm · TCGA-ACC | — | — | Adrenal Cortical Carcinoma | 1 | Observed | gdc | graph → |